Vascular Biology Group
Goal: To identify pathways linking inflammation and thrombosis and to develop novel therapeutics targeted to specific vascular beds.
Blood fluidity is maintained by endothelial surface proteins, vasodilators secreted by endothelial cells and inhibitors of coagulant cascades. Inflammatory conditions, autoimmune diseases and ischaemic injury alter the vascular bed making it prothrombotic and amplify organ damage in a positive feed-back loop. Our group has identified an essential role for endothelial phosphohydrolase ‘NTPDase, CD39’ in the maintenance of endothelial function in the context of ischaemic, oxidative and immune-mediated activation. We have developed novel endothelial-targeted therapeutics with specificity to activated vascular beds thereby delivering benefit with minimal systemic bleeding compromise. We are exploring the role of purinergic nucleotides (ATP, ADP, adenosine) and complement proteins in the causation of thrombosis and miscarriages in patients with Lupus (SLE), antiphospholipid syndrome (APS) and thrombotic microangiopathy (TMA).
We are developing state-of-art platforms based on microfluidic technology to screen chemical libraries for antithrombotic potential and develop point-of-care devices for the diagnosis and management of haemostatic disorders.
2016. Professor Harshal Nandurkar, Ms Susanna Freddi , Ms Carly Selan, Dr Sharelle Sturgeon, Ms Lucinda Green,
Dr Warwick Nesbitt, Ms Rose Brazilek, Absent: Ms Kate Firipis, Ms Anushka Samudra.
Projects and Opportunities
- To test a novel endothelial-targeted antithrombotic in murine models of renal ischaemia reperfusion injury, coronary thrombosis and stroke
- To dissect the role of ADP and adenosine signaling in the pathogenesis of thrombosis and miscarriages in SLE and antiphospholipid syndrome
- To study the role of chaperone GRP78 as an endogenous haemostasis inhibitor
- To develop and test microfluidic devices for the diagnosis of von Willebrand disease and coagulopathies
For current project opportunity descriptions please visit our honours page
Chan, K., Filshie, R.J.A., Nandurkar, H.H., Quach, H., 2015, Thrombotic microangiopathy complicating bortezomib-based therapy, Leukemia & Lymphoma [P], vol 56, issue 7, Informa Healthcare, London United Kingdom, pp. 2185-2186.
Filshie, R.J.A., Ong, J., Yeung, D.T., Hughes, T.P., Nandurkar, H.H., 2015, Imatinib-induced gastric antral vascular ectasia in three patients with chronic myeloid leukaemia, International Journal of Hematology [P], vol 1, Springer Japan KK, Tokyo Japan, pp. 1-4.
Kamel, S., Horton, L., Ysebaert, L., Levade, M., Burbury, K.L., Tan, S., Cole-Sinclair, M.F., Reynolds, J.D., Filshie, R.J.A., Schischka, S., Khot, A.S., Sandhu, S.K., Keating, M.J., Nandurkar, H., Tam, C.S., 2015, Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation, Leukemia [P], vol 29, issue 4, Nature Publishing Group, London United Kingdom, pp. 783-787.
Ku, M., Wall, M., MacKinnon, R.N., Walkley, C.R., Purton, L.E., Tam, C.S., Izon, D.J., Campbell, L.J., Cheng, H., Nandurkar, H., 2015, Src family kinases and their role in hematological malignancies, Leukemia & Lymphoma [P], vol 56, issue 3, Informa Healthcare, London United Kingdom, pp. 577-586.
Holwell, A., McKenzie, J., Holmes, M., Woods, R., Nandurkar, H.H., Tam, C.S., Bazargan, M.A., 2014, Venous thromboembolism prevention in patients undergoing colorectal surgery for cancer, ANZ Journal of Surgery [P], vol 84, issue 4, Wiley-Blackwell Publishing Asia, Richmond Victoria Australia, pp. 284-288.
Ku, M., Bazargan, M.A., Nandurkar, H.H., Tam, C.S., 2014, Effective treatment of Waldenstrom macroglobulinemia associated pure red cell aplasia with standard antilymphomatous chemotherapy, Leukemia & Lymphoma [P], vol 55, issue 3, Informa Healthcare, London United Kingdom, pp. 692-694.
Meretoja, A., Churilov, L., Campbell, B.C.V., Aviv, R.I., Yassi, N., Barras, C.D.J., Mitchell, P.J., Yan, B., Nandurkar, H.H., Bladin, C.F., Wijeratne, T., Spratt, N., Jannes, J., Sturm, J.W., Rupasinghe, J., Zavala, J.A., Lee, A., Kleinig, T.J., Markus, R., Delcourt, C., Mahant, N., Parsons, M.W., Levi, C.R., Anderson, C.S., Donnan, G., Davis, S.M., 2014, The Spot sign and Tranexamic acid On Preventing ICH growth - AUStralasia Trial (STOP-AUST): Protocol of a phase II randomized, placebo-controlled, double-blind, multicenter trial, International Journal Of Stroke [P], vol 9, issue 4, Wiley-Blackwell Publishing Asia, Richmond Victoria Australia, pp. 519-524.
Morrisroe, K.B., Stevens, W.M.R., Nandurkar, H.H., Prior, D.L., Thakkar, V., Roddy, J., Zochling, J., Sahhar, J.M., Tymms, K.E., Sturgess, A.D., Major, G., Kermeen, F., Hill, C.M., Walker, J.G., Nash, P.T., Gabbay, E., Youssef, P.P., Proudman, S.M., Nikpour, M., 2014, The association of antiphospholipid antibodies with cardiopulmonary manifestations of systemic sclerosis, Clinical and Experimental Rheumatology [E], vol 32, issue 6, Pacini Editore SpA, Ospedaletto Italy, pp. 133-137.
Nandurkar, H.H., Chong, B.H., Salem, H.H., Gallus, A., Ferro, V., McKinnon, R.A., 2014, Low-molecular-weight heparin biosimilars: Potential implications for clinical practice, Internal Medicine Journal [P], vol 44, issue 5, Wiley-Blackwell Publishing Asia, Richmond Victoria Australia, pp. 497-500.
Tran, H.A., Joseph, J.E., Young, L., McRae, S., Curnow, J., Nandurkar, H., Wood, P., McLintock, C.K., 2014, New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management, Internal Medicine Journal [P], vol 44, issue 6, Wiley-Blackwell Publishing Asia, Australia, pp. 525-536.
Zordan, R., Manitta, V., Nandurkar, H.H., Cole-Sinclair, M.F., Philip, J.A.M., 2014, Prevalence and predictors of fatigue in haemo-oncological patients, Internal Medicine Journal [P], vol 44, issue 10, Wiley-Blackwell Publishing Asia, Richmond Victoria Australia, pp. 1013-1017.